UBS Maintains Neutral on Amgen, Lowers Price Target to $268
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Colin Bristow has maintained a Neutral rating on Amgen (NASDAQ:AMGN) and lowered the price target from $272 to $268.
November 01, 2023 | 6:48 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
UBS has maintained a Neutral rating on Amgen and lowered the price target from $272 to $268, which may influence investor sentiment.
The lowered price target by UBS may cause some investors to reassess their positions in Amgen, potentially leading to short-term price volatility. However, the maintained Neutral rating suggests that UBS does not anticipate significant changes in the stock's performance.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100